Things Just Got Worse for Biogen | The Motley Fool
That said, Biogen's Alzheimer's disease infusion therapy is currently undergoing phase 4 post-marketing studies. One of these trials is unfortunately a single-arm study, meaning it won't be compared to anything except historical values -- and, it is not estimated to garner results until October 2026. In light of this ongoing approval saga, it's hard to imagine that the CMS (and other insurance companies) would pay up for a treatment proven on only a single-arm study, as these are generally considered lower-quality evidence.
That said, Biogen's Alzheimer's disease infusion therapy is currently undergoing phase 4 post-marketing studies. One of these trials is unfortunately a single-arm study, meaning it won't be compared to anything except historical values -- and, it is not estimated to garner results until October 2026. In light of this ongoing approval saga, it's hard to imagine that the CMS (and other insurance companies) would pay up for a treatment proven on only a single-arm study, as these are generally considered lower-quality evidence.